Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammation of the joints and systemic complications. Conventional treatment options often result in systemic side effects and inadequate targeting of the affected tissues. Targeted drug delivery systems (TDDS) offer a promising strategy to enhance therapeutic efficacy while minimizing adverse effects. This article explores recent advancements in targeted drug delivery approaches for RA, including nanoparticle carriers, ligand-receptor targeting, and stimulus-responsive systems. The potential of these technologies to revolutionize RA treatment is discussed along with current limitations and future directions.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.